Boundless Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10955 Alexandria Way Ste 100, San Diego,...Phone Number
(858) 766-9912Website
www.boundlessbio.comRevenue
-Stock Symbol
BOLDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Boundless Bio
Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.Explore more
Boundless Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Boundless Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Boundless Bio recently announced quarterly report
Click to see if Boundless Bio had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Boundless Bio
Boundless Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Boundless Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Boundless Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Boundless Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Boundless Bio launches new products
Recommended Actions
Find VP level buyers at Boundless Bio
Find 2 more new buyers
Compare Similar Companies to Boundless Bio
Compare insights from companies similar to Boundless Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Boundless Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Boundless Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Boundless Bio.
Boundless Bio financials insights
Gather financial insights about Boundless Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$46.4M
2021
Series B
$105M
2023
Series C
$100M
Boundless Bio Tech Stack
A closer look at the technologies used by Boundless Bio
Most Recent Scoops
Person-Based
Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events, Search, Medical Research
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Boundless Bio News & Media
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancersBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollmentBoundless Bio to Participate in the Leerink Global Healthcare Conference
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Boundless Bio
Sign Up For FreeTo access detailed company insights
Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.... Read More
